CA-4948
Modify Date: 2024-01-02 14:15:32
CA-4948 structure
|
Common Name | CA-4948 | ||
|---|---|---|---|---|
| CAS Number | 1801344-14-8 | Molecular Weight | 491.50 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C24H25N7O5 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of CA-4948CA-4948 is a potent, selective and orally bioavailable IRAK4 kinase inhibitor with an IC50 of < 50 nM. CA-4948 can be used for the treatment of lymphoma[1]. |
| Name | CA-4948 |
|---|
| Description | CA-4948 is a potent, selective and orally bioavailable IRAK4 kinase inhibitor with an IC50 of < 50 nM. CA-4948 can be used for the treatment of lymphoma[1]. |
|---|---|
| Related Catalog | |
| Target |
IRAK4:50 nM (IC50) |
| In Vivo | CA-4948 is a selective and potent IRAK4 kinase inhibitor with in vivo activity in a TLR4-induced cytokine release model. CA-4948 exhibits favorable drug metabolism and pharmacokinetic (DMPK) properties, oral bioavailability, and is well tolerated in mice. Moreover, CA-4948 exhibits dose-dependent efficacy in activated B-cell (ABC)-DLBCL MYD88-L265P xenograft tumor models using cell lines OCI-LY3 and OCI-LY10. CA-4948 exhibits the greatest efficacy in four of the five ABC-DLBCL PDX models tested as compared to GBC-DLBCL and ABC/GCB DLBCL patient-derived DLBCL tumor xenograft (PDX) models. Furthermore, CA-4948 is efficacious in ABC-DLBCL PDX tumors containing activating mutations in both TLR/IL-1R and BCR signaling pathways (MYD88 and CD79B double mutants)[2]. |
| References |
| Molecular Formula | C24H25N7O5 |
|---|---|
| Molecular Weight | 491.50 |
| Storage condition | -20°C |
| Hazard Codes | Xn |
|---|